undefined
A multicenter randomized clinical trial led by investigators at the Wake Forest University School of Medicine Pain Outcomes Lab indicates that high-frequency spinal cord stimulation can successfully diminish chronic pain and enhance sensory function in individuals suffering from treatment-resistant painful diabetic neuropathy. The findings, published in the journal Diabetes Care, also revealed early indications of increased small nerve-fiber density within the skin, prompting investigators to call for further study to understand the clinical significance and permanence of these structural changes.
Diabetic neuropathy represents a widespread, debilitating complication of diabetes characterized by chronic discomfort, numbness, and a loss of protective sensation, particularly in the lower extremities. As this nerve damage advances, affected individuals frequently face severe balance difficulties, stubborn foot ulcers, and an elevated risk of lower-limb amputation. Conventional clinical strategies have historically focused on symptom management, generally failing to reverse established damage or reliably restore lost sensation.
To evaluate a potential alternative, researchers conducted the Painful Diabetic Neuropathy Sensory study, investigating a 10-kHz spinal cord stimulation system. This medical technology involves surgically placing slender electrical leads near the spinal cord alongside a compact pulse generator positioned beneath the skin. The implanted device delivers mild electrical currents designed to modify how pain signals are transmitted to the central nervous system, operating without generating the uncomfortable tingling sensations commonly associated with older neurostimulation platforms.
Robert W. Hurley, corresponding author, professor of pain medicine and anesthesiology, and principal investigator at the Wake Forest University School of Medicine, noted that patients dealing with painful diabetic neuropathy routinely endure persistent suffering despite exhausting standard medications and therapies. Many trial participants reported significant pain relief and restored sensory capabilities, improvements that may assist them in performing daily activities with greater safety and comfort.
The clinical investigation enrolled 91 adult patients diagnosed with diabetes and chronic, treatment-resistant painful diabetic neuropathy across 13 medical centers in the United States. Participants were assigned at random to receive either standard medical management alone or a combination of spinal cord stimulation and conventional medical management. Over a six-month monitoring period, investigators tracked pain levels, sensory performance, sleep quality, and overall quality of life. To maintain rigorous standards, sensory testing and nerve-fiber analyses from skin biopsies were conducted by researchers blinded to individual treatment assignments.
Utilizing a conservative statistical approach that accounted for missing data, the trial demonstrated that 79.4% of participants who underwent temporary spinal cord stimulation achieved a minimum 50% reduction in lower-limb discomfort, contrasted with 4% of individuals managed through conventional medical care alone. Among patients who received a permanent neurostimulator implant and completed the six-month evaluation, 93.1% achieved at least a 50% decrease in pain.
Furthermore, the trial successfully met its primary sensory endpoint. Among participants completing the six-month follow-up, 55.2% of those utilizing spinal cord stimulation demonstrated meaningful enhancements in detecting touch, temperature, vibration, and body position, compared to 25% in the control group. Patients utilizing the therapy additionally reported noticeable improvements in sleep quality and general well-being.
Skin biopsy evaluations revealed an average 56% increase in small nerve-fiber density within the lower calf for participants receiving the neurostimulation therapy, while the conventional treatment group displayed no significant structural alterations. Researchers emphasized that the study was not structured to prove whether nerve fibers actively regenerated or whether the intervention fundamentally alters the underlying disease progression.
While pain reduction aligned with previous scientific literature, Hurley noted that objective enhancements in sensory metrics and nerve-fiber density were particularly encouraging. These observations hint at potential therapeutic effects reaching beyond basic symptom suppression, though extended follow-up remains necessary to verify whether the structural changes endure over time.
Study authors acknowledged specific limitations, including the open-label nature of the trial—where participants knew their treatment allocation—which could potentially influence subjective reporting, although evaluating clinicians remained blinded. Additionally, the trial was halted early after meeting predefined effectiveness criteria, a factor that can occasionally amplify apparent treatment effects. Because the cohort primarily comprised individuals with severe, treatment-resistant pathology, the outcomes may not directly generalize to patients with milder forms of neuropathy.
Researchers plan to track participants through a 12-month milestone to evaluate the long-term persistence of sensory recovery and nerve-fiber density changes, while future investigations will aim to clarify the underlying biological mechanisms.
Source: MedPage Today